Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Phire Hot Start DNA Polymerase

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 16 February 2001:
Vol. 291. no. 5507, p. 1203
DOI: 10.1126/science.291.5507.1203
Prev | Table of Contents | Next

News Focus

Can Data Banks Tally Profits?

Robert F. Service

Celera's high-powered sequencing has achieved impressive results, but it hasn't yet translated into a healthy bottom line. Like most biotech start-ups, the nearly-3-year-old company has yet to turn a profit. And, although the company's stock rocketed after going public in May 1999, its price tanked over the past year, along with that of other biotechs, from a high of $275 a share to about $50 today.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)